NO2493478T3 - - Google Patents
Info
- Publication number
- NO2493478T3 NO2493478T3 NO10825905A NO10825905A NO2493478T3 NO 2493478 T3 NO2493478 T3 NO 2493478T3 NO 10825905 A NO10825905 A NO 10825905A NO 10825905 A NO10825905 A NO 10825905A NO 2493478 T3 NO2493478 T3 NO 2493478T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25610609P | 2009-10-29 | 2009-10-29 | |
PCT/CA2010/001720 WO2011050474A1 (en) | 2009-10-29 | 2010-10-29 | Concentrated therapeutic phospholipid compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2493478T3 true NO2493478T3 (no) | 2018-07-21 |
Family
ID=43921214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO10825905A NO2493478T3 (no) | 2009-10-29 | 2010-10-29 |
Country Status (23)
Country | Link |
---|---|
US (4) | US8586567B2 (no) |
EP (2) | EP2493478B8 (no) |
JP (3) | JP5827625B2 (no) |
KR (1) | KR101788342B1 (no) |
CN (2) | CN104434935B (no) |
AR (1) | AR078850A1 (no) |
AU (1) | AU2010312238C1 (no) |
CA (2) | CA2989078C (no) |
CL (1) | CL2012001124A1 (no) |
DK (1) | DK2493478T3 (no) |
ES (1) | ES2663714T3 (no) |
HK (1) | HK1208800A1 (no) |
IL (2) | IL219457B (no) |
MX (2) | MX366175B (no) |
NO (1) | NO2493478T3 (no) |
NZ (1) | NZ600167A (no) |
PT (1) | PT2493478T (no) |
RU (2) | RU2642653C2 (no) |
SA (1) | SA110310813B1 (no) |
TW (2) | TWI573591B (no) |
UY (1) | UY32989A (no) |
WO (1) | WO2011050474A1 (no) |
ZA (1) | ZA201203367B (no) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002322233C1 (en) * | 2001-07-27 | 2014-02-13 | Aker Biomarine Antarctic As | Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
DK2144618T3 (da) | 2007-03-28 | 2013-06-17 | Aker Biomarine As | Bioeffektive krill-olie-sammensætninger |
US20130295171A1 (en) | 2009-07-23 | 2013-11-07 | U.S NUTRACEUTICALS, LLC d/b/a Valensa International | Krill oil and reacted astaxanthin composition and associated method |
TWI573591B (zh) | 2009-10-29 | 2017-03-11 | 阿卡斯提製藥公司 | 經濃縮治療性磷脂質組合物 |
US8974818B2 (en) * | 2010-01-20 | 2015-03-10 | Henry Wu | Custom-formulated phospholipid microbubbles and methods and uses thereof |
US9763897B2 (en) | 2010-04-30 | 2017-09-19 | U.S. Nutraceuticals, LLC | Therapeutic astaxanthin and phospholipid composition and associated method |
US8663704B2 (en) * | 2010-04-30 | 2014-03-04 | U.S. Nutraceuticals, LLC | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans |
US8952000B2 (en) * | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
CN102210764B (zh) * | 2011-05-30 | 2013-04-17 | 陕西师范大学 | 甜杏仁油在制备治疗心肌缺血再灌注损伤药物中应用 |
WO2013033618A1 (en) | 2011-09-02 | 2013-03-07 | Arctic Nutrition As | Lipid compositions with high dha content |
RU2464986C1 (ru) * | 2011-11-09 | 2012-10-27 | Вячеслав Анатольевич Игнатьев | Способ проф. игнатьева снижения массы тела человека |
WO2013149384A1 (en) * | 2012-04-05 | 2013-10-10 | Nippon Suisan Kaisha, Ltd. | Brain atrophy prevention agent |
CA2916208A1 (en) * | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
SG11201500379QA (en) | 2012-07-19 | 2015-03-30 | Us Nutraceuticals Llc Dba Valensa Int | Krill oil and reacted astaxanthin composition and associated method |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
WO2014158256A1 (en) * | 2013-03-13 | 2014-10-02 | Matinas Biopharma Inc. | Omega-3 pentaenoic acid compositions and methods of use |
AU2014229540A1 (en) * | 2013-03-14 | 2015-10-08 | Aker Biomarine Antarctic As | Omega- 3 phospholipid supplements for improved brain maturity |
AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
US9549937B2 (en) | 2013-12-05 | 2017-01-24 | Burvia, LLC. | Composition containing phospholipid-DHA and folate |
US9233114B2 (en) | 2013-12-05 | 2016-01-12 | Buriva, LLC | Dietary supplement containing phospholipid-DHA derived from eggs |
US9610302B2 (en) | 2013-12-05 | 2017-04-04 | Buriva, LLC. | Composition containing phospholipid-DHA and B vitamins |
US9216199B2 (en) | 2013-12-05 | 2015-12-22 | Buriva, LLC | Nutritional supplement containing phospholipid-DHA derived from eggs |
GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
GB201402450D0 (en) | 2014-02-12 | 2014-03-26 | Aker Biomarine As | Liquid phospholipid-containing compositions for preperation of pharmaceuticals |
GB201402457D0 (en) | 2014-02-12 | 2014-03-26 | Aker Biomarine As | Capsules containing high doses of phospholipids |
WO2015142999A1 (en) * | 2014-03-19 | 2015-09-24 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to improve blood lipid profiles and reduce low density lipoprotein (ldl) per-oxidation in humans using algae based oils and astaxanthin |
GB201407345D0 (en) | 2014-04-25 | 2014-06-11 | Aker Biomarine As | Krill Phospholipid compositions |
EP3232798A1 (en) | 2014-12-19 | 2017-10-25 | Aker Biomarine Antarctic AS | Enhanced omega-3 formulations |
EP3256553A2 (en) * | 2015-02-11 | 2017-12-20 | Aker Biomarine Antarctic AS | Lipid compositions |
DE102015106095A1 (de) * | 2015-04-21 | 2016-10-27 | K. D. Pharma Bexbach Gmbh | Neue Anwendung von Omega-3-Fettsäure(n) |
US10328105B2 (en) | 2015-05-27 | 2019-06-25 | Rimfrost Technologies As | Flowable concentrated phospholipid krill oil composition |
WO2017031502A1 (en) * | 2015-08-20 | 2017-02-23 | Avoca, Inc. | Method for increasing muscle growth using krill extract |
WO2017211780A1 (en) * | 2016-06-06 | 2017-12-14 | Ludwig-Maximilians-Universitaet Muenchen | Kaempferol for the treatment of cardiac diseases |
CN106336433B (zh) * | 2016-08-22 | 2018-04-27 | 浙江大学 | 一种拟南芥活性组分提取物及其制备方法和应用 |
TWI815840B (zh) * | 2017-12-22 | 2023-09-21 | 香港商法瑪林克國際有限公司 | 脂質組合 |
CN109198628A (zh) * | 2018-10-10 | 2019-01-15 | 陶燃 | 一种治疗抑郁症及焦虑症的组合物及其用途 |
EP3923966A4 (en) * | 2019-02-12 | 2023-01-04 | Acasti Pharma Inc. | PROCESS FOR PREPARING A CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITION FROM KRILL EXTRACTS HIGH IN FREE FATTY ACIDS |
US20220162238A1 (en) | 2019-03-05 | 2022-05-26 | Sichuan Gowell Pharmaceutical Co., Ltd. | Fatty acid composition and application thereof |
EP3958973A4 (en) * | 2019-04-26 | 2023-06-07 | Cytosolve, Inc. | COMPOSITIONS TO IMPROVE BRAIN HEALTH AND MEMORY |
WO2021138742A1 (en) * | 2020-01-10 | 2021-07-15 | Acasti Pharma Inc. | Composition that promote pro-resolving mediators |
WO2022140580A1 (en) * | 2020-12-24 | 2022-06-30 | Orn Almarsson | Xanthophyll derivatives |
WO2023107415A1 (en) * | 2021-12-06 | 2023-06-15 | The Children's Medical Center Corporation | Compositions comprising modified phospholipids and uses thereof |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT331374B (de) | 1972-12-22 | 1976-08-25 | Studiengesellschaft Kohle Mbh | Verfahren zur gewinnung von fetten und olen aus pflanzlichen und tierischen produkten |
JPS5248191B2 (no) | 1974-12-27 | 1977-12-08 | ||
JPS53112195A (en) | 1977-03-10 | 1978-09-30 | Nippon Paint Co Ltd | Method for producing food for fish |
CA1098900A (en) | 1977-12-14 | 1981-04-07 | Sergei V. Rogozhin | Method for the processing of krill to produce protein, lipids and chitin |
JPS6029463B2 (ja) | 1978-08-09 | 1985-07-10 | 味の素株式会社 | オキアミエキスの品質改善法 |
NO147365C (no) | 1980-11-27 | 1983-03-30 | Jan Raa | Fremgangsmaate til fremstilling av astaxanthin i en form som er egnet for innlemmelse i for for oppdrettfisk. |
WO1984001715A1 (en) | 1982-10-25 | 1984-05-10 | Hellgren Lars G I | Enzyme composition for therapeutical and/or non-therapeutical cleaning, the use thereof and preparation of the composition |
JPS59196032A (ja) | 1983-04-23 | 1984-11-07 | Fumio Nishikawa | オキアミの変性防止及び鮮度保持の方法 |
JPS603507A (ja) | 1983-06-21 | 1985-01-09 | Hitachi Ltd | 配線パタ−ン検出装置 |
JPS60153779A (ja) | 1984-01-24 | 1985-08-13 | Hohnen Oil Co Ltd | 栄養補助食品 |
JPS6035057A (ja) | 1984-06-27 | 1985-02-22 | San Ei Chem Ind Ltd | 黄橙色ないし赤橙色色素の製法 |
US5006281A (en) | 1985-03-26 | 1991-04-09 | Century Laboratories, Inc. | Process for the production of a marine animal oil |
IT1187687B (it) | 1985-07-17 | 1987-12-23 | Inverni Della Beffa Spa | Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi |
IT1215291B (it) | 1985-07-17 | 1990-01-31 | Inverni Della Beffa Spa | Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche. |
JPS6323819A (ja) | 1986-07-16 | 1988-02-01 | Kao Corp | 血小板凝集抑制剤 |
IT1201149B (it) | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche |
IT1201151B (it) | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono |
JPS63295698A (ja) | 1987-05-27 | 1988-12-02 | Showa Denko Kk | α−リノレン酸の分離精製法 |
US4915876A (en) | 1987-07-20 | 1990-04-10 | General Mills, Inc. | Process for the deodorization and stabilization of polyunsaturated oils |
JPS6450890A (en) | 1987-08-20 | 1989-02-27 | Nippon Oils & Fats Co Ltd | Production of docosahexaenoic acid-containing phosphatidyl choline |
JPH02167055A (ja) | 1988-12-19 | 1990-06-27 | Seiji Nojima | 機能性練製品 |
JP2909508B2 (ja) * | 1989-02-14 | 1999-06-23 | マルハ株式会社 | オキアミリン脂質の分取方法 |
JP2963152B2 (ja) | 1990-06-28 | 1999-10-12 | クロリンエンジニアズ株式会社 | オキアミからの色素の抽出分離方法 |
JP3092180B2 (ja) | 1991-02-27 | 2000-09-25 | 日本油脂株式会社 | 低密度リポ蛋白受容体活性化剤 |
EP0507363B1 (en) | 1991-04-02 | 1993-05-19 | N.V. Vandemoortele International | Process for the continuous removal of a gum phase from triglyceride oil |
SE9101642D0 (sv) | 1991-05-30 | 1991-05-30 | Kabi Pharmacia Ab | Phospholipids |
DE4219360C2 (de) | 1992-06-12 | 1994-07-28 | Milupa Ag | Verfahren zur Gewinnung von Lipiden mit einem hohen Anteil von langkettig-hochungesättigten Fettsäuren |
GB9301629D0 (en) | 1993-01-27 | 1993-03-17 | Scotia Holdings Plc | Formulations containing unsaturated fatty acids |
JP2558050B2 (ja) | 1993-02-18 | 1996-11-27 | イセ食品株式会社 | 鶏用飼料 |
GB2290965A (en) * | 1994-07-11 | 1996-01-17 | Therapicon Srl | Multiple layer capsules for drugs |
JPH08198754A (ja) | 1995-01-23 | 1996-08-06 | Yakult Honsha Co Ltd | 脳機能改善剤 |
ES2088750B1 (es) | 1995-01-24 | 1997-03-01 | Cruz Bartolome A Grillo | Procedimiento para la preparacion y conservacion de un suplemento alimenticio natural a base del crustaceo euphasia superba del antartico aplicable para el consumo humano. |
JP3398248B2 (ja) | 1995-03-16 | 2003-04-21 | 新日本石油株式会社 | キサントフィル化合物の精製方法 |
JPH08302382A (ja) | 1995-05-09 | 1996-11-19 | Nippon Synthetic Chem Ind Co Ltd:The | 魚油の精製法 |
GB9510636D0 (en) | 1995-05-25 | 1995-07-19 | Scotia Holdings Plc | Fatty acid treatment |
JPH09124470A (ja) | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
JP2815562B2 (ja) | 1995-11-13 | 1998-10-27 | 植田製油株式会社 | 高度不飽和脂肪酸含有油脂の精製方法 |
WO1997039759A2 (en) * | 1996-04-24 | 1997-10-30 | Brigham And Women's Hospital | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder |
JPH10155459A (ja) * | 1996-11-27 | 1998-06-16 | Suntory Ltd | アスタキサンチン含有飲食物 |
US6055936A (en) | 1997-01-21 | 2000-05-02 | Collin; Peter Donald | Sea cucumber carotenoid lipid fractions and process |
US6852870B2 (en) | 1999-03-22 | 2005-02-08 | Andrew Stoll | Omega-3 fatty acids in the treatment of depression |
US7906153B2 (en) | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
JP4727039B2 (ja) | 1998-06-05 | 2011-07-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 汚染物質低下魚油 |
JP2000060432A (ja) * | 1998-08-27 | 2000-02-29 | Nippon Kagaku Shiryo Kk | 高度不飽和脂肪酸を多量に含有する高品質リン脂質の製造法 |
CA2251265A1 (en) * | 1998-10-21 | 2000-04-21 | Universite De Sherbrooke | Process for lipid extraction of aquatic animal tissues producing a dehydrated residue |
US20030113432A1 (en) | 1998-11-02 | 2003-06-19 | Nippon Suisan Kaisha, Ltd. | Process for making dried powdery and granular krill |
CA2260397A1 (en) | 1999-01-29 | 2000-07-29 | Atlantis Marine Inc. | Method of converting rendered triglyceride oil from marine sources into bland, stable food oil |
CA2290885A1 (fr) | 1999-12-02 | 2001-06-02 | Universite De Sherbrooke | Methode pour la transformation des tissus du loup marin |
KR100344907B1 (ko) | 1999-12-13 | 2002-07-20 | 네오메가(주) | 정제 어유 제조방법 |
KR20020037140A (ko) | 2000-11-13 | 2002-05-18 | 권승룡 | 지질 저하 활성을 갖는 플라보노이드를 포함하는 터몹시스알터니플로라 추출물 및 이를 유효 성분으로 하는 약학적조성물 |
CA2325377A1 (en) | 2000-11-14 | 2002-05-14 | Adrien R. Beaudoin | Process for the extraction of lipids from bird's skin and fat tissues |
IL142952A (en) | 2001-05-03 | 2005-12-18 | Enzmotec Ltd | Process for enzyme-catalyzed production of 1,2 diacylated phospholipids |
EP1392623A4 (en) | 2001-05-14 | 2005-05-04 | Martek Biosciences Corp | PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS |
DK1406641T3 (da) * | 2001-06-18 | 2009-05-04 | Neptune Technologies & Bioress | Krillekstrakter til forebyggelse og/eller behandling af cardiovaskulære sygdomme |
AU2002322233C1 (en) | 2001-07-27 | 2014-02-13 | Aker Biomarine Antarctic As | Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
US7488503B1 (en) | 2003-03-31 | 2009-02-10 | Mccormick & Company, Inc. | Encapsulation compositions and processes for preparing the same |
WO2005011712A1 (en) * | 2003-07-25 | 2005-02-10 | Washington State University Research Foundation | Natural astaxanthin extract reduces dna oxidation |
JP4903569B2 (ja) | 2003-09-12 | 2012-03-28 | アクセス ビジネス グループ インターナショナル エルエルシー | サイトカインモジュレータ及び関係する使用法 |
IL158552A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Lipids containing omega-3 fatty acids |
US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
US7572464B2 (en) | 2004-01-30 | 2009-08-11 | Bionovate Limited | Solvent extraction of lipids such as essential fatty acids |
TW200811280A (en) | 2006-04-20 | 2008-03-01 | Owen John Catchpole | Product and process |
WO2008149177A2 (en) | 2006-05-05 | 2008-12-11 | Natural Asa | Marine lipid compositions and uses thereof |
US20080021000A1 (en) | 2006-07-19 | 2008-01-24 | Su Chen | Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species |
JP2010510208A (ja) * | 2006-11-16 | 2010-04-02 | プロノヴァ バイオファーマ ノルゲ アーエス | オキアミ油およびミールの製造方法 |
US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
DK2144618T3 (da) | 2007-03-28 | 2013-06-17 | Aker Biomarine As | Bioeffektive krill-olie-sammensætninger |
US20090118227A1 (en) | 2007-11-07 | 2009-05-07 | Bristol-Myers Squibb Company | Carotenoid-containing compositions and methods |
EP2085089A1 (en) * | 2008-02-01 | 2009-08-05 | KTB-Tumorforschungs GmbH | Phospholipids Containing omega-3-Fatty Acids for the Treatment of Overweight, Obesity and Addictive Behavior |
WO2009132463A1 (en) | 2008-05-02 | 2009-11-05 | Neptune Technologies & Bioressources Inc. | New deodorization method and organoleptic improvement of marine oil extracts |
CN101333229A (zh) | 2008-05-10 | 2008-12-31 | 中国海洋大学 | 一种提取富含二十碳五烯酸及二十二碳六烯酸磷脂的方法 |
SG174314A1 (en) | 2009-03-09 | 2011-10-28 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
WO2010109330A2 (en) * | 2009-03-27 | 2010-09-30 | University Of Oxford | Cholesterol level lowering liposomes |
TWI573591B (zh) | 2009-10-29 | 2017-03-11 | 阿卡斯提製藥公司 | 經濃縮治療性磷脂質組合物 |
WO2011137160A2 (en) * | 2010-04-30 | 2011-11-03 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans |
-
2010
- 2010-10-29 TW TW104113741A patent/TWI573591B/zh active
- 2010-10-29 DK DK10825905.2T patent/DK2493478T3/en active
- 2010-10-29 KR KR1020127013588A patent/KR101788342B1/ko active IP Right Grant
- 2010-10-29 RU RU2012122059A patent/RU2642653C2/ru active
- 2010-10-29 US US12/915,724 patent/US8586567B2/en active Active
- 2010-10-29 CN CN201410490601.5A patent/CN104434935B/zh active Active
- 2010-10-29 CN CN201080059930.4A patent/CN102753182B/zh active Active
- 2010-10-29 TW TW099137397A patent/TWI494110B/zh not_active IP Right Cessation
- 2010-10-29 CA CA2989078A patent/CA2989078C/en active Active
- 2010-10-29 UY UY0001032989A patent/UY32989A/es not_active Application Discontinuation
- 2010-10-29 EP EP10825905.2A patent/EP2493478B8/en active Active
- 2010-10-29 MX MX2014010299A patent/MX366175B/es unknown
- 2010-10-29 MX MX2012004977A patent/MX2012004977A/es active IP Right Grant
- 2010-10-29 ES ES10825905.2T patent/ES2663714T3/es active Active
- 2010-10-29 EP EP18152030.5A patent/EP3335713B1/en active Active
- 2010-10-29 NO NO10825905A patent/NO2493478T3/no unknown
- 2010-10-29 AU AU2010312238A patent/AU2010312238C1/en active Active
- 2010-10-29 CA CA2779162A patent/CA2779162C/en active Active
- 2010-10-29 AR ARP100104020A patent/AR078850A1/es not_active Application Discontinuation
- 2010-10-29 WO PCT/CA2010/001720 patent/WO2011050474A1/en active Application Filing
- 2010-10-29 NZ NZ600167A patent/NZ600167A/en unknown
- 2010-10-29 PT PT108259052T patent/PT2493478T/pt unknown
- 2010-10-29 RU RU2017139767A patent/RU2755902C2/ru not_active Application Discontinuation
- 2010-10-29 JP JP2012535564A patent/JP5827625B2/ja active Active
- 2010-10-30 SA SA110310813A patent/SA110310813B1/ar unknown
-
2012
- 2012-04-27 CL CL2012001124A patent/CL2012001124A1/es unknown
- 2012-04-29 IL IL219457A patent/IL219457B/en active IP Right Grant
- 2012-05-09 ZA ZA2012/03367A patent/ZA201203367B/en unknown
-
2013
- 2013-10-15 US US14/054,588 patent/US9475830B2/en active Active
-
2015
- 2015-04-10 JP JP2015081001A patent/JP6346121B2/ja not_active Expired - Fee Related
- 2015-09-25 HK HK15109467.8A patent/HK1208800A1/xx unknown
-
2016
- 2016-09-07 US US15/258,044 patent/US10130644B2/en active Active
-
2018
- 2018-05-21 JP JP2018096807A patent/JP2018138612A/ja active Pending
- 2018-09-19 US US16/135,212 patent/US10617702B2/en active Active
- 2018-10-24 IL IL262567A patent/IL262567B/en unknown